300406 九强生物
已收盘 12-25 15:00:00
资讯
新帖
简况
九强生物：病理AI项目处于临床验证阶段
证券之星 · 12-24 20:48
九强生物：病理AI项目处于临床验证阶段
九强生物：推进欧美东南亚市场产品注册
证券之星 · 12-24 20:48
九强生物：推进欧美东南亚市场产品注册
九强生物(300406.SZ)取得三项医疗器械注册证书
智通财经 · 12-24 15:48
九强生物(300406.SZ)取得三项医疗器械注册证书
九强生物：指南发布短期内不会影响公司利润
证券之星 · 12-24 15:42
九强生物：指南发布短期内不会影响公司利润
股市必读：12月23日九强生物发布公告，股东增持30.5万股
证券之星 · 12-24 03:55
股市必读：12月23日九强生物发布公告，股东增持30.5万股
九强生物（300406）披露取得医疗器械注册证书，12月15日股价下跌1.93%
证券之星 · 12-15
九强生物（300406）披露取得医疗器械注册证书，12月15日股价下跌1.93%
九强生物获果糖胺测定试剂盒医疗器械注册证
中金财经 · 12-15
九强生物获果糖胺测定试剂盒医疗器械注册证
九强生物（300406）披露股东拟协议转让部分股份暨权益变动提示性公告，12月10日股价上涨2.89%
证券之星 · 12-10
九强生物（300406）披露股东拟协议转让部分股份暨权益变动提示性公告，12月10日股价上涨2.89%
九强生物最新公告：取得医疗器械注册证书
证券之星 · 12-09
九强生物最新公告：取得医疗器械注册证书
九强生物(300406.SZ)取得一项医疗器械注册证
智通财经 · 11-27
九强生物(300406.SZ)取得一项医疗器械注册证
九强生物（300406）披露关于九强转债恢复转股的提示性公告，11月26日股价上涨0.07%
证券之星 · 11-26
九强生物（300406）披露关于九强转债恢复转股的提示性公告，11月26日股价上涨0.07%
九强生物（300406）披露可转债转股价格调整公告，11月24日股价上涨1.59%
证券之星 · 11-24
九强生物（300406）披露可转债转股价格调整公告，11月24日股价上涨1.59%
九强生物（300406）披露关于实施权益分派期间九强转债暂停转股的提示性公告，11月18日股价下跌1.24%
证券之星 · 11-18
九强生物（300406）披露关于实施权益分派期间九强转债暂停转股的提示性公告，11月18日股价下跌1.24%
九强生物最新公告：股东拟减持不超0.38%股份
证券之星 · 11-11
九强生物最新公告：股东拟减持不超0.38%股份
九强生物：肿瘤病理研发投入持续增加
证券之星 · 11-04
九强生物：肿瘤病理研发投入持续增加
九强生物(300406.SZ)取得两项医疗器械注册证
智通财经 · 11-03
九强生物(300406.SZ)取得两项医疗器械注册证
九强生物（300406）2025年三季报简析：净利润同比下降27.03%，公司应收账款体量较大
中金财经 · 10-30
九强生物（300406）2025年三季报简析：净利润同比下降27.03%，公司应收账款体量较大
九强生物（300406）披露全资子公司增持厦门龙进生物科技有限公司股权暨关联交易公告，10月29日股价下跌0.3%
证券之星 · 10-29
九强生物（300406）披露全资子公司增持厦门龙进生物科技有限公司股权暨关联交易公告，10月29日股价下跌0.3%
图解九强生物三季报：第三季度单季净利润同比下降20.96%
证券之星 · 10-29
图解九强生物三季报：第三季度单季净利润同比下降20.96%
九强生物(300406.SZ)取得一项医疗器械注册证书
智通财经 · 10-22
九强生物(300406.SZ)取得一项医疗器械注册证书
加载更多
公司概况
公司名称：
北京九强生物技术股份有限公司
所属行业：
医药制造业
上市日期：
2014-10-30
主营业务：
北京九强生物技术股份有限公司的主营业务是打造多元化、高质量体外诊断检测平台，目前拥有病理诊断系统、生化诊断系统、血凝诊断系统、发光诊断系统、血型诊断系统、POCT诊断系统和液体活检系统。公司的主要产品是病理诊断系统、生化诊断系统、血凝诊断系统、发光诊断系统、血型诊断系统、POCT诊断系统和液体活检系统。2025年1月14日，公司荣获“军事科学技术进步一等奖”。
发行价格：
14.32
{"stockData":{"symbol":"300406","market":"SZ","secType":"STK","nameCN":"九强生物","latestPrice":13.42,"timestamp":1766646213000,"preClose":13.29,"halted":0,"volume":3231300,"delay":0,"changeRate":0.0098,"floatShares":424000000,"shares":586000000,"eps":0.7364,"marketStatus":"已收盘","change":0.13,"latestTime":"12-25 15:00:00","open":13.35,"high":13.5,"low":13.27,"amount":43218100,"amplitude":0.0173,"askPrice":13.43,"askSize":3,"bidPrice":13.42,"bidSize":60,"shortable":0,"etf":0,"ttmEps":0.7364,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766712600000},"marketStatusCode":5,"adr":0,"adjPreClose":13.29,"symbolType":"stock","openAndCloseTimeList":[[1766626200000,1766633400000],[1766638800000,1766646000000]],"highLimit":14.62,"lowLimit":11.96,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":586308628,"isCdr":false,"pbRate":2.04,"roa":"--","peRate":18.223791,"roe":"6.73%","epsLYR":0.92,"committee":0.40936,"marketValue":7868000000,"turnoverRate":0.0076,"status":0,"floatMarketCap":5696000000},"requestUrl":"/m/hq/s/300406","defaultTab":"news","newsList":[{"id":"2593723964","title":"九强生物：病理AI项目处于临床验证阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2593723964","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593723964?lang=zh_cn&edition=full","pubTime":"2025-12-24 20:48","pubTimestamp":1766580531,"startTime":"0","endTime":"0","summary":"投资者提问：国家医保局12月19日发布的病理检查诊断价格立项精细化文件对公司的AI病理诊断是利好么？目前子公司迈新生物的AI病理诊断涵盖了多少省市和医院？指南的发布，从政策层面认可AI在病理诊断中的应用价值，为病理数字化和新技术应用提供了制度基础，有阶段性积极意义。病理AI相关项目是公司重点研发项目，当前，在研产品尚处于临床验证阶段，后续相关进展请以公司公告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400037250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","300406","BK0012","BK0028","BK0046"],"gpt_icon":0},{"id":"2593047258","title":"九强生物：推进欧美东南亚市场产品注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2593047258","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593047258?lang=zh_cn&edition=full","pubTime":"2025-12-24 20:48","pubTimestamp":1766580530,"startTime":"0","endTime":"0","summary":"证券之星消息，九强生物12月24日在投资者关系平台上答复投资者关心的问题。公司目前着力推进欧美、东南亚等重点市场的产品注册和分销渠道建设工作。海外医疗机构对精准诊断和病理数字化需求日益提升，国内病理AI企业在软硬件方面积淀深厚，已具备出海基础。公司坚持临床价值导向，将持续推进与知名头部公司的业务合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400037249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0077","BK0012","300406","BK0028"],"gpt_icon":0},{"id":"2593427518","title":"九强生物(300406.SZ)取得三项医疗器械注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2593427518","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593427518?lang=zh_cn&edition=full","pubTime":"2025-12-24 15:48","pubTimestamp":1766562483,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九强生物(300406.SZ)发布公告，公司于近日收到北京市药品监督管理局颁发的《医疗器械注册证》，涉及产品：“D-二聚体校准品”、“降钙素测定试剂盒(磁微粒化学发光免疫分析法)”、“霉酚酸测定试剂盒(IMPDHⅡ法)”。上述产品医疗器械注册证的取得，丰富了公司在体外诊断生化、化学发光及血凝细分领域产品线的品种，有利于进一步提升公司的核心竞争力和市场拓展能力，对公司未来的经营将产生积极影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","159883","300406","BK0028","09997","09996","BK0046","BK0239","BK0012","BK1100","BK1574","BK1222","BK0077"],"gpt_icon":0},{"id":"2593427384","title":"九强生物：指南发布短期内不会影响公司利润","url":"https://stock-news.laohu8.com/highlight/detail?id=2593427384","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593427384?lang=zh_cn&edition=full","pubTime":"2025-12-24 15:42","pubTimestamp":1766562129,"startTime":"0","endTime":"0","summary":"请问最近病理医疗服务价格立项指南发布，请问这个指南的发布对公司的近期利润和未来前景会产生什么样的影响九强生物回复：您好，感谢您对公司的关注。指南发布主要是统一和规范病理服务价格项目的管理框架，为各省后续制定具体收费标准提供依据。该指南目前主要确立项目和定价规则，而非直接定价，短期内不会对公司利润产生直接影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400019747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","300406","BK0046","BK0077","BK0239"],"gpt_icon":0},{"id":"2593841013","title":"股市必读：12月23日九强生物发布公告，股东增持30.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2593841013","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593841013?lang=zh_cn&edition=full","pubTime":"2025-12-24 03:55","pubTimestamp":1766519714,"startTime":"0","endTime":"0","summary":"来自股本股东变化：股东中国医药投资有限公司在2025年9月23日至12月22日期间增持30.5万股，增持后持股比例达18.49%。股本股东变化股东增减持12月23日九强生物发布公告《九强生物:关于公司持股5%以上股东增持公司股份计划实施完毕的公告》，其股东中国医药投资有限公司于2025年9月23日至2025年12月22日间合计增持30.5万股，占公司目前总股本的0.052%，变动期间该股股价下跌0.37%，截止12月22日收盘报13.33元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400002677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0012","300406","BK0239","BK0046","BK0028"],"gpt_icon":0},{"id":"2591617949","title":"九强生物（300406）披露取得医疗器械注册证书，12月15日股价下跌1.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591617949","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591617949?lang=zh_cn&edition=full","pubTime":"2025-12-15 18:03","pubTimestamp":1765792994,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘，九强生物报收于13.21元，较前一交易日下跌1.93%，最新总市值为77.45亿元。该股当日开盘13.3元，最高13.34元，最低13.16元，成交额达6124.7万元，换手率为1.09%。公司近日发布公告称，北京九强生物技术股份有限公司近日收到北京市药品监督管理局颁发的《医疗器械注册证》，产品为果糖胺测定试剂盒，注册证编号京械注准20252400983，注册类别Ⅱ类，有效期至2030年12月08日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500023716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","159883","09996","BK1583","BK1100","300406","09997","BK1222","BK0046","BK0077","BK0239","BK0012","BK1574"],"gpt_icon":0},{"id":"2591261188","title":"九强生物获果糖胺测定试剂盒医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2591261188","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591261188?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:39","pubTimestamp":1765787954,"startTime":"0","endTime":"0","summary":"中访网数据 北京九强生物技术股份有限公司近日宣布，其“果糖胺测定试剂盒(NBT法)”已获得由北京市药品监督管理局颁发的医疗器械注册证(注册证编号：京械注准20252400983)。该注册证类别为Ⅱ类，有效期自批准之日起至2030年12月08日。该产品为雅培仪器封闭通道配套专用试剂，用于体外定量测定人血清中果糖胺的含量。公司表示，此次新产品的获批丰富了其在体外诊断生化细分领域的产品线，有助于提升核心竞争力及市场拓展能力。不过，公司也提示，该产品的实际销售情况将取决于未来的市场推广效果，目前尚无法预测其对未来业绩的具体影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251215/31866001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","300406","BK1583","09997","BK0046","BK1222","BK0012","BK1100","BK0077","159883","BK0028","BK0239","09996"],"gpt_icon":0},{"id":"2590995583","title":"九强生物（300406）披露股东拟协议转让部分股份暨权益变动提示性公告，12月10日股价上涨2.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590995583","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590995583?lang=zh_cn&edition=full","pubTime":"2025-12-10 17:51","pubTimestamp":1765360285,"startTime":"0","endTime":"0","summary":"截至2025年12月10日收盘，九强生物报收于13.88元，较前一交易日上涨2.89%，最新总市值为81.38亿元。该股当日开盘13.8元，最高13.93元，最低13.61元，成交额达1.35亿元，换手率为2.3%。转让完成后，国药投资持股比例由18.49%增至23.49%。本次转让不触及要约收购，不构成关联交易，不会导致公司控制权变更。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000028967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0012","300406","BK0239","BK0046","BK0028"],"gpt_icon":0},{"id":"2590170953","title":"九强生物最新公告：取得医疗器械注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590170953","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590170953?lang=zh_cn&edition=full","pubTime":"2025-12-09 18:39","pubTimestamp":1765276780,"startTime":"0","endTime":"0","summary":"九强生物(300406.SZ)公告称，公司近日收到北京市药品监督管理局颁发的《医疗器械注册证》，产品包括D-二聚体测定试剂盒（磁微粒化学发光免疫分析法）和D-二聚体测定试剂盒（胶乳免疫比浊法）。这些注册证的取得丰富了公司在体外诊断化学发光及血凝细分领域产品线的品种，有利于提升公司的核心竞争力和市场拓展能力，对公司未来的经营将产生积极影响。但实际销售情况取决于未来市场推广效果，公司目前无法预测其对未来业绩的影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900030082.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09997","BK0012","BK0239","09996","BK0046","BK0028","BK0077","BK1222","BK1100","BK1583","300406","BK1574","159883"],"gpt_icon":0},{"id":"2586217297","title":"九强生物(300406.SZ)取得一项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2586217297","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586217297?lang=zh_cn&edition=full","pubTime":"2025-11-27 15:48","pubTimestamp":1764229737,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九强生物(300406.SZ)公告，公司近日收到北京市药品监督管理局颁发的《医疗器械注册证》，产品名称为：轻链κ测定试剂盒(免疫比浊法)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159883","BK1574","BK0012","BK1100","BK1222","BK1583","300406","09996","BK0028","BK0046","09997","BK0077","BK0239"],"gpt_icon":0},{"id":"2586263489","title":"九强生物（300406）披露关于九强转债恢复转股的提示性公告，11月26日股价上涨0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586263489","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586263489?lang=zh_cn&edition=full","pubTime":"2025-11-26 22:40","pubTimestamp":1764168021,"startTime":"0","endTime":"0","summary":"截至2025年11月26日收盘，九强生物报收于13.46元，较前一交易日上涨0.07%，最新总市值为78.92亿元。该股当日开盘13.48元，最高13.65元，最低13.38元，成交额达5005.72万元，换手率为0.87%。公司近日发布公告称，因实施2025年第二次中期权益分派，九强转债自2025年11月19日至2025年11月26日暂停转股。根据相关规定，九强转债将于权益分派股权登记日后的第一个交易日，即2025年11月27日起恢复转股。公司提醒债券持有人注意相关安排。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600039235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","300406","BK0239","BK0012","BK0077"],"gpt_icon":0},{"id":"2585849811","title":"九强生物（300406）披露可转债转股价格调整公告，11月24日股价上涨1.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585849811","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585849811?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:36","pubTimestamp":1763994990,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，九强生物报收于13.38元，较前一交易日上涨1.59%，最新总市值为78.45亿元。该股当日开盘13.18元，最高13.49元，最低13.11元，成交额达5356.45万元，换手率为0.95%。公司近日发布公告称，因实施2025年第二次中期权益分派，向全体股东每10股派发现金2.000000元人民币（含税），根据可转债转股价格调整条款，对“九强转债”转股价格进行调整。调整后转股价格由16.68元/股下调至16.48元/股，自2025年11月27日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400036241.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0012","300406","BK0028","BK0077"],"gpt_icon":0},{"id":"2584933747","title":"九强生物（300406）披露关于实施权益分派期间九强转债暂停转股的提示性公告，11月18日股价下跌1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584933747","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584933747?lang=zh_cn&edition=full","pubTime":"2025-11-18 18:03","pubTimestamp":1763460223,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，九强生物报收于13.51元，较前一交易日下跌1.24%，最新总市值为79.21亿元。该股当日开盘13.72元，最高13.74元，最低13.5元，成交额达5057.21万元，换手率为0.88%。近日，九强生物发布关于实施权益分派期间九强转债暂停转股的提示性公告。公告称，北京九强生物技术股份有限公司将于2025年实施第二次中期权益分派，根据相关规定，九强转债自2025年11月19日起至权益分派股权登记日止暂停转股，股权登记日后的第一个交易日起恢复转股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800028346.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406","BK0028","BK0046","BK0239","BK0012","BK0077"],"gpt_icon":0},{"id":"2582654073","title":"九强生物最新公告：股东拟减持不超0.38%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2582654073","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582654073?lang=zh_cn&edition=full","pubTime":"2025-11-11 19:59","pubTimestamp":1762862376,"startTime":"0","endTime":"0","summary":"九强生物(300406.SZ)公告称，持股5%以上的自然人股东ZHOUXIAOYAN计划自公告披露之日起十五个交易日后的三个月内，通过集中竞价和/或大宗交易方式减持公司股份不超过221.42万股（占公司总股本的0.38%），减持原因为自身资金需求。减持期间为公告披露之日起十五个交易日后的三个月内（即2025年12月3日至2026年3月2日）。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100035829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0077","BK0028","BK0239","300406","BK0012"],"gpt_icon":0},{"id":"2580527299","title":"九强生物：肿瘤病理研发投入持续增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2580527299","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580527299?lang=zh_cn&edition=full","pubTime":"2025-11-04 11:33","pubTimestamp":1762227188,"startTime":"0","endTime":"0","summary":"证券之星消息，九强生物(300406)11月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，贵司在肿瘤病理研发方面有没有增加投入资金？九强生物回复：您好，感谢您对公司的关注。肿瘤病理是我们长期聚焦的核心战略方向。近年来公司在该领域的研发投入持续增加，以巩固我们在肿瘤诊断领域的领先地位，并推动创新成果的临床转化。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400014493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406","BK0012","BK0028","BK0046","BK0077","BK0239"],"gpt_icon":0},{"id":"2580129261","title":"九强生物(300406.SZ)取得两项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2580129261","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580129261?lang=zh_cn&edition=full","pubTime":"2025-11-03 15:53","pubTimestamp":1762156397,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九强生物(300406.SZ)公告，公司近日收到北京市药品监督管理局颁发的《医疗器械注册证》，产品名称分别为：肝素结合蛋白测定试剂盒(磁微粒化学发光免疫分析法)、全自动生化分析仪(型号：Gc2000、Gc2400)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09997","BK0046","BK0028","159883","09996","BK0012","BK0239","BK1583","BK1100","BK1222","300406","BK0077"],"gpt_icon":0},{"id":"2579715623","title":"九强生物（300406）2025年三季报简析：净利润同比下降27.03%，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2579715623","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579715623?lang=zh_cn&edition=full","pubTime":"2025-10-30 08:06","pubTimestamp":1761782764,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期九强生物发布2025年三季报。截至本报告期末，公司营业总收入10.12亿元，同比下降18.24%，归母净利润2.72亿元，同比下降27.03%。按单季度数据看，第三季度营业总收入3.43亿元，同比下降17.39%，第三季度归母净利润9722.7万元，同比下降20.96%。本报告期九强生物公司应收账款体量较大，当期应收账款占最新年报归母净利润比达192.14%。然而去年的净利率为32.02%，算上全部成本后，公司产品或服务的附加值极高。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202510/30/20251030441913.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202510/30/20251030441913.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251030/31748835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300406"],"gpt_icon":0},{"id":"2579923973","title":"九强生物（300406）披露全资子公司增持厦门龙进生物科技有限公司股权暨关联交易公告，10月29日股价下跌0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579923973","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579923973?lang=zh_cn&edition=full","pubTime":"2025-10-29 17:53","pubTimestamp":1761731593,"startTime":"0","endTime":"0","summary":"九强生物近日发布公告称，公司全资子公司福州迈新生物技术开发有限公司拟以自有资金3,529.80万元收购厦门龙进生物科技有限公司22.27%股权，对应注册资本530.00万元。本次交易完成后，迈新生物将持有龙进生物47.48%股权。本次交易构成关联交易，已获公司第五届董事会第二十一次会议及独立董事专门会议审议通过，无需提交股东大会审议。公司与龙进生物本年年初至公告日累计发生关联交易653,006.72元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900037642.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406","BK0046","159837","BK0239","BK0077","BK0012","BK0028"],"gpt_icon":0},{"id":"2579995922","title":"图解九强生物三季报：第三季度单季净利润同比下降20.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579995922","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579995922?lang=zh_cn&edition=full","pubTime":"2025-10-29 03:12","pubTimestamp":1761678779,"startTime":"0","endTime":"0","summary":"证券之星消息，九强生物2025年三季报显示，公司主营收入10.12亿元，同比下降18.24%；归母净利润2.72亿元，同比下降27.03%；扣非净利润2.7亿元，同比下降27.21%；其中2025年第三季度，公司单季度主营收入3.43亿元，同比下降17.39%；单季度归母净利润9722.7万元，同比下降20.96%；单季度扣非净利润9672.55万元，同比下降21.42%；负债率24.55%，投资收益-104.27万元，财务费用3104.49万元，毛利率79.86%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900003382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406"],"gpt_icon":0},{"id":"2577935592","title":"九强生物(300406.SZ)取得一项医疗器械注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2577935592","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577935592?lang=zh_cn&edition=full","pubTime":"2025-10-22 15:50","pubTimestamp":1761119400,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九强生物(300406.SZ)发布公告，公司于近日收到北京市药品监督管理局颁发的《医疗器械注册证》，产品名称：地高辛测定试剂盒(磁微粒化学发光免疫分析法)，该试剂盒用于体外定量测定人血清或血浆中地高辛(DIG)的含量。上述产品医疗器械注册证的取得，丰富了公司在体外诊断化学发光细分领域产品线的品种，有利于进一步提升公司的核心竞争力和市场拓展能力，对公司未来的经营将产生积极影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300406","BK1583","BK0012","159883","BK1222","BK1574","BK1100","BK0077","09997","BK0046","09996","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766696026864,"stockEarnings":[{"period":"1week","weight":0.0098},{"period":"1month","weight":0.0128},{"period":"3month","weight":0.0181},{"period":"6month","weight":0.0216},{"period":"1year","weight":0.0258},{"period":"ytd","weight":0.0719}],"compareEarnings":[{"period":"1week","weight":0.0215},{"period":"1month","weight":0.0232},{"period":"3month","weight":0.0344},{"period":"6month","weight":0.1564},{"period":"1year","weight":0.1669},{"period":"ytd","weight":0.1814}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京九强生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"18058人(较上一季度减少2.48%)","perCapita":"23502股","listingDate":"2014-10-30","address":"北京市海淀区花园东路15号旷怡大厦5层","registeredCapital":"58630万元","survey":" 北京九强生物技术股份有限公司的主营业务是打造多元化、高质量体外诊断检测平台，目前拥有病理诊断系统、生化诊断系统、血凝诊断系统、发光诊断系统、血型诊断系统、POCT诊断系统和液体活检系统。公司的主要产品是病理诊断系统、生化诊断系统、血凝诊断系统、发光诊断系统、血型诊断系统、POCT诊断系统和液体活检系统。2025年1月14日，公司荣获“军事科学技术进步一等奖”。","listedPrice":14.32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九强生物(300406)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九强生物(300406)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九强生物,300406,九强生物股票,九强生物股票老虎,九强生物股票老虎国际,九强生物行情,九强生物股票行情,九强生物股价,九强生物股市,九强生物股票价格,九强生物股票交易,九强生物股票购买,九强生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九强生物(300406)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九强生物(300406)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}